US: LGNZZ - Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt

半年間の収益性: -31.58%
配当利回り: 0.00%

プロモーションスケジュール Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt


会社について Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide.

さらに詳しく
Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Валюта usd
Валюта отчета usd
Сайт https://www.ligand.com
Цена ао 0.1227
1日あたりの価格変動: +5.95% (0.1227)
週ごとの価格変動: +5.95% (0.1227)
月ごとの料金変更: 0% (0.13)
3ヶ月間の価格変動: -1.89% (0.1325)
半年間の価格変動: -31.58% (0.19)
年間の価格変動: +22.64% (0.106)
3年間の価格推移: +622.22% (0.018)
5年間の価格推移: 0% (0.13)
10年間の価格推移: 0% (0.13)
年初からの価格変動: -1.89% (0.1325)

過小評価

名前 意味 学年
P/S 0.0145 10
P/BV 0.0029 10
P/E 0.2673 10
EV/EBITDA 2.78 10
合計: 8.75

効率

名前 意味 学年
ROA, % 1.05 1
ROE, % 1.18 1
合計: 0.6667

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.3143 10
合計: 8.8

成長の衝動

名前 意味 学年
収益性 Revenue, % -10.35 0
収益性 Ebitda, % -161.6 0
収益性 EPS, % -368.82 0
合計: 1.8

スーパーバイザー 役職 支払い 生年
Mr. Todd C. Davis Ph.D. CEO & Director 1961 (64 年)
Mr. Matthew E. Korenberg President & COO 1975 (50 年)
Mr. Octavio Espinoza Chief Financial Officer 1971 (54 年)
Mr. Andrew T. Reardon J.D. Chief Legal Officer & Secretary 1975 (50 年)
Mr. Paul J. Hadden Senior Vice President of Investments & Business Development
Michael Jeong Head of Investor Relations
Mr. Todd Pettingill Director of Corporate Development
Dr. Keith Marschke Senior Vice President of Biology & Scientific Affairs
Dr. Vincent D. Antle Senior Vice President of Technical Operations & QA - Capitsol 1969 (56 年)
Mr. Patrick Lucy Senior VP & CBO Protein Expression Business

住所: United States, Jupiter, 555 Heritage Drive - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.ligand.com